GAL-201

GAL-201 is an orally administered small molecule drug candidate developed as a disease-modifying therapy for Alzheimer’s disease. It belongs to a new pharmacological class of amyloid beta (Aβ) aggregation modulators, specifically designed to bind with high affinity and selectivity to misfolded Aβ monomers. By targeting these misfolded forms, GAL-201 prevents their aggregation into toxic oligomers and protofibrils—key drivers of neurodegeneration in Alzheimer’s disease—while sparing normal Aβ monomers necessary for synaptic plasticity. The compound has demonstrated the ability to detoxify soluble Aβ oligomers, protect long-term potentiation (LTP), improve cognitive performance in animal models, reduce neuroinflammation, and lower the number of toxic Aβ plaques. Its mechanism includes seeding self-replicating non-toxic aggregates that may provide long-lasting effects even after drug withdrawal. GAL-201 is currently in preclinical development with plans for IND-enabling studies[1][2][3][4][5][6][7][8].